Daniel Schaufelberger P.hD.
VP CMC, NGT BioPharma Consultants LLC and Adjunct Assistant Professor, Johns Hopkins University School of Medicine
Pharmaceutical executive with over 25 years of experience in pharmaceutical development, including pediatric products. Daniel retired from Janssen R&D LLC (Johnson & Johnson) as Sr. Scientific Director, CMC Leader, where he co-chaired the J&J internal Pediatric Formulation Network. He is an independent consultant in pediatric pharmaceutical development and general aspects of Chemistry, Manufacturing and Controls. He recently joined NGT BioPharma Consultants LLC as VP of CMC. Daniel holds a degree in Pharmacy (ETH Zurich) and a “Doctorat en Pharmacie” from the University of Lausanne, Switzerland. He did postdoctoral studies in the US and worked for Sandoz Pharma, Switzerland before joining Johnson & Johnson and relocating to the US. Daniel has worked on a broad range of dosage forms and across different therapeutic areas in global product development. He is a member of the IQ Pediatric Working Group and has been appointed Formulation Expert for the pan-European “Conect4Children” initiative. Daniel is a founding member of the society of “Paediatric Medicines and Health Initiative”, based in Mumbai, India. He is a Scientific Advisor for the Swiss Tropical & Public Health Institute, University of Basel, Switzerland. In 2020, he joined Johns Hopkins University, School of Medicine, All Children’s Hospital in St. Petersburg, FL as adjunct assistant Professor, Neurology. Daniel is interested in Artificial Intelligence/Machine Learning and recently established an AI/ML focus group, part of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ). Daniel is a speaker and moderator at domestic and international conferences with a focus and passion for “developing better medicines for children”.